Selegiline hydrochloride.
Each tablet contains: Selegiline hydrochloride 5 mg.
Mitochondrial monoamine oxidase (MAO) is classified into 2 main types, type A and type B. SEFMEX is a selective inhibitor of the B-type MAO. The 2 enzymes are unevenly distributed in the body. In the human intestine MAO-A is present, and in the human brain, MAO-B is present, MAO-A is responsible for the breakdown of serotonin, epinephrine and norepinephrine. The selective substrate for MAO-B is phenylethylamine. Dopamine is metabolised by both enzymes. The human nigrostriatal neurons, that play an important role in Parkinson syndrome, contain MAO-B. As an inhibitor of this enzyme, SEFMEX increases the dopamine store in the dopamine deficient neurons and administered in combination with Levodopa, it produces a high dopamine concentration in the corpus striatum. It increases the effect of Levodopa effect and prolongs the duration of it's action. It does not inhibit the breakdown of other monoamines therefore, it is free from the hazard of side effects (hypertensive crises) induced by the traditional non-selective MAOIs.
As a monotherapy in the incipient stage of Parkinson syndrome. At the initiation of substitution therapy for the adjuvation of Levodopa effect. While efficacy of the therapy is maintained, in certain cases the Levodopa dose can be reduced.
The usual initial daily dose is 1-2 tablets in the morning or in 2 divided doses at breakfast and lunch time.
Combined Therapy: In case of the administration of SEFMEX the dose of the Levodopa-substituent may be reduce, it usually does not influence the application of other anti-parkinsonian agents (parasympatholytics, amantadine, etc).
Extrapyramidal disorders unrelated to dopamine deficiency (essential familiar tremor, Huntington's chorea, etc).
SEFMEX therapy of Levodopa-treated Parkinsonism patients should be adjusted in neurological departments of in-patient institutes. The patient should be controlled at 3 month intervals preferably at the department adjusting the therapy. If it is not possible, the control examination should be performed in special out-patient care units.
Serotonergic psychiatric drugs should not be started in a patient receiving Linezolid. Wait until 24 hours after the last dose of Linezolid before starting the serotonergic psychiatric drugs.
They are identical with those observed after Levodopa overdosage. If Levodopa dose are not reduced on the basis of the patient's response, both its cerebral effects (hallucination, confusion and hyperkinesia) and its extracerebral effects (first of all gastro-intestinal complaints) may increase. If combined, Levodopa and additional SEFMEX treatment is more favorable, as the risk of extracerebral side effects may decrease.
Store at temperature not more than 30°C.
N04BD01 - selegiline ; Belongs to the class of dopaminergic agents, monoamine oxidase B inhibitors. Used in the management of Parkinson's disease.
Sefmex tab 5 mg
10 × 10's
Sign Out
